ADC Linker

4-Pentynoyl-Val-Ala-PAB-PNP is a cleavable linker specifically designed for antibody-drug conjugates (ADCs). This reagent facilitates the synthesis of cryptophycin conjugates and features an alkyne functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAC) with azide-containing molecules. Its applications extend to the development of targeted therapeutics, enhancing the efficacy of drug delivery systems.

Endo-BCN-Fmoc-L-Lysine is a specialized linker featuring the bidentate macrocyclic ligand endo-BCN, designed for use in antibody-drug conjugate (ADC) applications. This compound facilitates the synthesis of macrocyclic complexes and participates in click chemistry, where it can react with azide-containing molecules to form stable triazoles without the need for catalysts. Its properties make it particularly valuable in bioconjugation and therapeutic development research.

Mal-amide-PEG8-Val-Cit-PAB-OH is a cleavable ADC linker designed to facilitate targeted drug delivery in antibody-drug conjugates. The maleimide group enables covalent attachment to free thiols present on cysteine residues in proteins, while the hydrophilic PEG spacer enhances solubility and reduces immunogenicity. Upon internalization, the Val-Cit dipeptide is cleaved by cellular proteases, allowing for the efficient release of the therapeutic payload, aided by the PAB functional group. This linker is suitable for use in cancer research and therapeutic development.

Arg-Phe-Asp-Ser is a cleavable linker designed for antibody-drug conjugates (ADCs). It facilitates the release of cytotoxic agents specifically within target cells, thereby enhancing the therapeutic efficacy of ADCs while minimizing off-target effects. This linker is crucial for research applications focused on developing innovative cancer therapies and improving drug delivery systems.

Fmoc-PEG4-Val-Cit-PAB-OH is an enzyme-cleavable linker designed for antibody-drug conjugates (ADCs), incorporating a hydrophilic PEG spacer and a Val-Cit-PAB dipeptide. The structure includes a benzylic alcohol on the PAB, facilitating conjugation with reactive drug payloads. Upon Fmoc group removal with piperidine, a primary amine is exposed, enabling further coupling reactions to create amide bonds. The Val-Cit-PAB motif is selectively cleaved by cellular proteases, allowing for the effective release of therapeutic agents within target cells.

N-Boc-N-methyl-D-Valaldehyde functions as an ADC linker, featuring a BOC protecting group that enhances stability during synthesis and application. This compound facilitates the conjugation of antibodies to cytotoxic agents, playing a crucial role in the development of antibody-drug conjugates (ADCs) for targeted cancer therapies. Its structural attributes make it suitable for research applications focused on optimizing ADC design and efficacy.

NHS-cBu-Cit-PAB is a versatile intermediate used in the synthesis of antibody-drug conjugates (ADCs). It functions as an active ester linker that facilitates the conjugation of antibodies to cytotoxic drugs, enhancing targeted delivery and therapeutic efficacy. This reagent is essential for researchers developing ADCs aimed at improving cancer treatment methodologies.

Azido-PEG8-Amido-Val-Cit-PAB is a cleavable linker designed for antibody-drug conjugates (ADCs), targeting Cathepsin B for selective payload release within lysosomes. The Val-Cit moiety ensures that drug release occurs specifically in the intracellular environment, enhancing therapeutic efficacy while minimizing systemic toxicity. The azido group allows for efficient conjugation to DBCO, BCN, or other alkyne-containing molecules through click chemistry. The polyethylene glycol (PEG) spacer improves aqueous solubility, making this reagent suitable for various research applications in drug development.

SCO-PEG2-Maleimide is an ADC linker featuring a maleimide moiety and three polyethylene glycol (PEG) units. This compound serves as a valuable tool for copper-free click chemistry, enabling efficient conjugation in catalyst-free reactions. Its properties facilitate the stability and controlled release of therapeutic agents, making it suitable for drug delivery applications and the development of antibody-drug conjugates.

Azidoacetyl-Val-Cit-PAB-OH is a cleavable linker designed for antibody-drug conjugates (ADCs). This compound facilitates the selective delivery of cytotoxic agents to target cells while minimizing off-target effects. It can be utilized in the development of ADCs for cancer therapy, enhancing therapeutic efficacy through controlled drug release.

Boc-PEG4-Val-Cit-PAB-OH is an enzyme-cleavable linker designed for antibody-drug conjugates (ADCs). This compound features a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide, facilitating the attachment of drug payloads through reactive groups such as PNP. The Boc group can be removed via acidic treatment, yielding a primary amine suitable for forming amides through coupling reactions. The Val-Cit-PAB component is preferentially cleaved by cellular proteases, enabling efficient release of the cytotoxic payload within targeted cells.

β-Glu-PNP is an ADC linker that plays a critical role in the synthesis of antibody-drug conjugates (ADCs). It facilitates the stable attachment of cytotoxic drugs to antibodies, allowing for targeted delivery to cancer cells. This compound is essential for research applications focusing on the development and optimization of ADCs in cancer therapies.

MC-GGFG-NH-CH2-O-CH2-cyclopropane-COOH is a specialized ADC linker designed to facilitate the conjugation of cytotoxic agents to antibodies. This linker enables the formation of antibody-drug conjugates (ADCs) when combined with Camptothecin, a potent antitumor compound. The resulting drug-linker conjugates enhance targeted delivery and efficacy in cancer research applications, particularly in studies involving Trastuzumab.

NSC 135130 is a BOC-protected ADC linker designed for conjugation with tubulin-targeting inhibitors. This compound facilitates the synthesis of antibody-drug conjugates (ADCs), enhancing the delivery and efficacy of targeted therapies. Its utility in drug development makes it an important reagent for research applications focused on targeted cancer treatments.

N-[S-Trityl-L-cysteinyl]glycine is a cleavable linker specifically designed for antibody-drug conjugates (ADCs). This compound facilitates the selective release of cytotoxic drugs in targeted cancer therapy, enhancing the therapeutic efficacy while minimizing off-target effects. Its unique cleavage properties make it an important reagent in the development and optimization of ADCs for research applications in cancer treatment.

SCO-PEG3-Maleimide is a cleavable antibody-drug conjugate (ADC) linker featuring three polyethylene glycol (PEG) units. This compound facilitates copper-free click chemistry, enabling efficient catalyst-free reactions. The maleimide moiety undergoes degradation in aqueous environments, making it suitable for applications in drug delivery research and development.

N-Boc-N-methyl-D-Valinol is an ADC linker featuring a Boc protecting group. This compound plays a crucial role in the development of antibody-drug conjugates (ADCs), facilitating the stable attachment of cytotoxic agents to antibodies. It is particularly valuable in research focused on targeted therapies for cancer, allowing for enhanced specificity and reduced off-target effects in treatment applications.

Fmoc-PEG2-Val-Cit-PAB-OH is an enzyme-cleavable linker specifically designed for antibody-drug conjugates (ADCs). This compound features a hydrophilic PEG spacer and a Val-Cit-PAB dipeptide, which enables the selective release of therapeutic payloads inside target cells through proteolytic cleavage. The benzylic alcohol present in the PAB component can readily react with various functional groups for efficient conjugation to drug molecules, while the Fmoc protecting group can be deprotected using piperidine, allowing access to a primary amine for further coupling reactions. This linker is crucial for enhancing the efficacy and specificity of ADCs in biological research and therapeutic applications.

MC-Val-Ala-NHS ester is a cleavable antibody-drug conjugate (ADC) linker that features both a malimide group and an NHS ester group. It facilitates the specific cleavage of Val-Ala linkers by Cathepsin B while the maleimide moiety allows for selective conjugation to thiol groups. The NHS ester efficiently forms stable covalent bonds with amines, such as lysine side chains, under neutral or slightly basic conditions. This reagent is ideal for applications in ADC development, enabling targeted delivery of therapeutic agents.

Benzyl 2-cyclopropyl-2-hydroxyacetate serves as an essential intermediate in the synthesis of antibody-drug conjugate (ADC) linkers. This compound can be effectively coupled with cytotoxic agents like Exatecan and integrated with antibodies, such as hu2F7, to facilitate targeted delivery of therapeutic agents. Its application in ADC development enables enhanced specificity and reduced systemic toxicity for cancer treatment research.

Fmoc-PEG4-GGFG-CH2-O-CH2-Cbz is a cleavable linker designed for antibody-drug conjugates (ADCs), featuring a polyethylene glycol (PEG) moiety composed of four repeating units. This linker facilitates the synthesis of ADCs by enabling stable attachment to antibody molecules while allowing for controlled release of the cytotoxic payload. Its applications include the development of targeted therapies and the study of efficacy and delivery mechanisms in cancer research.

Alkyne-Val-Cit-PAB-OH is a cleavable linker designed for antibody-drug conjugates (ADCs). This compound facilitates the selective release of drug payloads within target cells, enhancing therapeutic efficacy while minimizing off-target effects. Its hydrophilic properties and favorable stability make it suitable for various ADC applications, including cancer therapy and targeted drug delivery research.

Boc-Gly-Sar-OH is a cleavable linker specifically designed for antibody-drug conjugates (ADCs). This compound facilitates the selective release of the cytotoxic agent upon internalization by target cells, enhancing the efficacy of ADCs in cancer therapeutics. Its biochemical properties make it suitable for research applications focused on targeted drug delivery and therapeutic development.

Fmoc-PEG6-Val-Cit-PAB-OH is an enzyme-cleavable linker designed for antibody-drug conjugates (ADCs) that comprises a hydrophilic PEG spacer, a Boc-protected amine, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB allows for conjugation with reactive groups, such as PNP, to facilitate the attachment of drug payloads. The Fmoc protecting group can be removed using piperidine, exposing a primary amine for subsequent amide bond formation. The Val-Cit-PAB moiety is efficiently cleaved by cellular proteases, ensuring targeted release of therapeutic agents within the cells.

NHS-Ala-Ala-Asn-active metabolite is a cleavable linker specifically designed for antibody-drug conjugates (ADCs), targeting kinesin spindle protein (KSP) inhibitors. This reagent facilitates the synthesis of ADCs by ensuring effective drug delivery to cancer cells through selective cleavage. Its key applications include the development and optimization of targeted cancer therapies, enhancing therapeutic efficacy while minimizing off-target effects.

Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB-PNP is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the selective release of cytotoxic agents upon internalization by target cells, enhancing the therapeutic efficacy of ADCs. It is ideal for applications in cancer research and the development of targeted therapies.

NH2-PEG3-Val-Cit-PAB-OH is a cleavable antibody-drug conjugate (ADC) linker that incorporates a primary amine, a hydrophilic PEG spacer, a Val-Cit dipeptide, and a PAB group. This compound is designed to enhance payload delivery by undergoing cleavage by cellular proteases, facilitating the release of the drug inside the target cells. The primary amine allows for versatile functionalization through reactions with carboxylic acids, reductive aminations, and various advanced coupling techniques, making it suitable for applications in drug development and targeted therapies.

t-Boc-N-amido-PEG4-Val-Cit is a protease-cleavable linker designed for antibody-drug conjugates (ADCs). This compound consists of a Boc-protected amine, a hydrophilic polyethylene glycol (PEG) spacer, and a Val-Cit dipeptide that can be cleaved by cellular proteases. The resulting carboxylic acid facilitates coupling reactions with amines to form amides. Upon removal of the Boc group under acidic conditions, a free primary amine is available for diverse chemical reactions, including coupling and reductive amination, making it a versatile tool in ADC development and modification.

NH2-PEG1-Val-Cit-PAB-OH is a cleavable antibody-drug conjugate (ADC) linker designed for efficient payload delivery. This reagent features a primary amine, a hydrophilic PEG spacer, a Val-Cit dipeptide, and a PAB group, enabling versatile coupling reactions with carboxylic acids, ketones, and aldehydes. The Val-Cit dipeptide undergoes proteolytic cleavage within cells, facilitating the release of drug payloads through an elimination mechanism associated with the PAB structure. This compound is ideal for ADC development and other related bioconjugation applications.

N-Boc-MeVal is an ADC linker featuring a BOC protecting group. This compound is utilized in the development of antibody-drug conjugates (ADCs), facilitating the stable attachment of cytotoxic agents to antibodies for targeted cancer therapies. Its chemical structure allows for efficient conjugation, enhancing the efficacy and selectivity of therapeutic agents in research applications focused on oncology and drug delivery systems.

BCN-exo-PEG2-NH2 is an ADC linker featuring two polyethylene glycol (PEG) units. This compound incorporates the hydrophilic bidentate macrocyclic ligand, BCN, facilitating the formation of macrocyclic complexes. In click chemistry applications, BCN efficiently reacts with azide-containing molecules, yielding stable triazoles without the need for catalysts, making it valuable for antibody-drug conjugate (ADC) development and other bioconjugation strategies.

NH2-PEG4-Val-Cit-PAB-OH is a cleavable antibody-drug conjugate (ADC) linker designed for targeted delivery of therapeutic payloads. Its structure includes a primary amine for versatile coupling reactions, a hydrophilic PEG spacer, and a Val-Cit dipeptide that is readily cleaved by cellular proteases, facilitating the release of the drug inside target cells. The PAB moiety enables efficient attachment of reactive groups, enhancing conjugation with drug payloads. This linker is valuable in research applications involving ADC development and optimization, enabling precise targeting in cancer therapy.

MC-GGFG-3-Methylenecyclobutyl functions as an ADC linker, facilitating the development of antibody-drug conjugates (ADCs). This compound enables stable conjugation between antibodies and cytotoxic drugs, enhancing targeted delivery to cancer cells. Its structural properties are designed to improve the efficacy and safety profile of therapeutic agents in cancer research and treatment.

(2R,3S)-3-(tert-Butoxy)-2-(4-ethyl-2,3-dioxopiperazine-1-carboxamido)butanoic acid serves as a versatile antibody-drug conjugate (ADC) linker. This compound is designed to facilitate the selective delivery of cytotoxic agents, enhancing the efficacy of targeted therapies. Its unique chemical structure promotes stability and solubility, making it suitable for various applications in oncology research and drug development.

Propargyl-PEG4-CH2CO2-NHS is an ADC linker that features a propargyl group and an N-hydroxysuccinimidyl (NHS) moiety. This compound facilitates the synthesis of antibody-drug conjugates (ADCs) by enabling selective coupling with amine-containing biomolecules. As a click chemistry reagent, it contains an alkyne functional group, allowing for efficient copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions with azide-containing partners. This versatile tool is essential for enhancing the potency and specificity of targeted therapeutics in bioconjugation applications.

Boc-PEG2-Val-Cit-PAB-OH is an enzyme-cleavable linker designed for antibody-drug conjugates (ADCs). The compound features a Boc-protected amine, a flexible PEG spacer, and a Val-Cit-PAB dipeptide, facilitating targeted delivery. The benzylic alcohol on the PAB moiety allows for the attachment of reactive groups for conjugation with drug payloads. Upon exposure to acidic conditions, the Boc group is removed to yield a primary amine for subsequent coupling reactions. The Val-Cit-PAB component is readily cleaved by cellular proteases, enabling the efficient release of therapeutic agents within target cells.

BCN-endo-PEG7-NH2 is a bifunctional ADC linker featuring a 7-unit PEG spacer and the lipophilic macrocyclic ligand endo-BCN. This compound enables efficient conjugation through click chemistry, allowing stable triazole formation with azide-containing molecules without the need for catalysts. BCN-endo-PEG7-NH2 is suitable for applications in antibody-drug conjugate (ADC) development and other bioconjugation techniques, facilitating targeted delivery and enhancing therapeutic efficacy in chemical biology research.

Alloc-Val-Ala-PAB-PNP is a cleavable ADC linker that facilitates targeted delivery of therapeutic agents. This compound effectively promotes the controlled release of payloads in targeted cells, enhancing specificity and minimizing off-target effects. It is particularly useful in the development of antibody-drug conjugates (ADCs) for cancer therapy, enabling researchers to investigate novel treatment strategies.

Alkyne-Val-Cit-PAB-PNP is a cleavable linker designed for antibody-drug conjugates (ADCs). This compound facilitates stable attachment of cytotoxic agents to antibodies while enabling release in the target tissues or cells via specific enzymatic cleavage. Its properties make it suitable for research applications focused on enhancing the efficacy and selectivity of ADCs in cancer therapy and related studies.

Mal-amido-PEG8-val-gly is a maleimide-based linker designed for antibody-drug conjugates (ADCs). This compound facilitates site-specific conjugation to thiol-containing biomolecules, enhancing the stability and therapeutic efficacy of the ADCs. It is particularly useful in the development of targeted cancer therapies by linking cytotoxic agents to antibodies, thereby enabling precise delivery to tumor cells.

(Ac)Phe-Lys(Alloc)-PABC-PNP is a cleavable chemical linker designed for use in antibody-drug conjugates (ADCs). It facilitates targeted delivery of therapeutic agents by linking the antibody to the drug while ensuring controlled release upon reaching the target site. This linker is valuable in the development of ADCs, enhancing their efficacy and minimizing off-target effects in cancer research and therapy.

Azido-PEG4-Ala-Ala-Asn(Trt)-PAB is a cleavable linker specifically designed for antibody-drug conjugates (ADCs). This compound facilitates the conjugation of antibodies to cytotoxic drugs, enhancing targeted delivery in cancer therapy. Its unique structure allows for selective cleavage in tumor environments, leading to effective drug release and improved therapeutic efficacy. Research applications include the development of novel ADCs and the exploration of targeted delivery mechanisms in oncology research.

Mal-amide-PEG8-Val-Cit-PAB-PNP is a cleavable antibody-drug conjugate (ADC) linker that targets thiol groups through its maleimide component, enabling selective labeling of cysteine residues in proteins. This linker incorporates an 8-unit polyethylene glycol (PEG) spacer for improved solubility and a Val-Cit dipeptide that is susceptible to cleavage by cytoplasmic peptidases, facilitating controlled drug release. The PAB and PNP carbonate groups enhance the linker’s reactivity, making it suitable for developing potent and targeted therapeutic agents in cancer research and other applications involving ADCs.

cBu-Cit-PAB is a crucial intermediate in the synthesis of antibody-drug conjugates (ADCs). It serves as a versatile linker that facilitates the attachment of cytotoxic agents to antibodies, enhancing targeted drug delivery. This compound is essential for research applications focused on developing innovative ADC formulations for cancer treatment.

Mm-C3-OSu (Methyl Maleate-C3-N-Hydroxysuccinimide Ester) serves as a chemically defined linker intermediate, featuring a cis-configured methyl maleate core with a C3 alkyl chain that is capped with an N-hydroxysuccinimide reactive group. This compound is specifically designed for the synthesis of stable antibody-drug conjugates (ADCs), facilitating targeted drug delivery in therapeutic applications. Its structural properties enable efficient conjugation, enhancing the stability and efficacy of ADC formulations in research and development.

NH2-PEG6-Val-Cit-PAB-OH is a cleavable antibody-drug conjugate (ADC) linker that incorporates a primary amine, a PEG spacer, a Val-Cit dipeptide, and a PAB group. This design facilitates the attachment of reactive groups, enabling the conjugation of drug payloads through the benzylic alcohol on the PAB moiety. The primary amine allows for versatile reactions, including coupling with carboxylic acids and reductive aminations. Within cells, the Val-Cit dipeptide is cleaved by proteases, promoting efficient drug release via the elimination mechanism inherent to the PAB structure, thus enhancing therapeutic efficacy in targeted delivery applications.

SCO-PEG7-Maleimide is a cleavable ADC linker incorporating three polyethylene glycol (PEG) units. This compound is designed for use in antibody-drug conjugates, facilitating targeted drug delivery. Its maleimide functional group enables efficient conjugation in aqueous environments, making it suitable for catalyst-free click chemistry applications. SCO-PEG7-Maleimide has significant utility in drug delivery research, particularly in studies focused on enhancing therapeutic efficacy and specificity.

Biotin-C2-S-S-pyridine is a cleavable linker designed for use in antibody-drug conjugates (ADCs). This compound facilitates the targeted delivery of cytotoxic agents to cancer cells by selectively releasing the drug upon internalization. Its biotin component allows for strong interactions with streptavidin-tagged proteins, enhancing the specificity and effectiveness of therapeutic applications in cancer research.

DBCO-NHS ester is a non-cleavable linker utilized in the synthesis of antibody-drug conjugates (ADCs). It serves as a click chemistry reagent, featuring a DBCO moiety that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. This compound is essential for bioconjugation applications, allowing for the stable attachment of therapeutics to antibodies, thereby enhancing the efficacy and specificity of targeted drug delivery in cancer research.

Sulfo-SMCC sodium is a hetero-bifunctional ADC linker that features both an N-hydroxysuccinimide (NHS) ester and a maleimide functional group. It facilitates efficient coupling by selectively reacting with primary amines and sulfhydryl groups, forming stable noncleavable linkages. This reagent is widely employed in the development of antibody-drug conjugates (ADCs), enabling targeted delivery of therapeutic agents for enhanced efficacy in cancer treatment and other diseases.